Method for determining the efficacy or sensitivity of anti-transferrin receptor antibodies
Intracellular iron levels serve as an indicator for determining the efficacy of anti-transferrin receptor antibodies, enabling effective treatment assessment in conditions like acute myeloid leukemia.
JP7875530B2Active Publication Date: 2026-06-18NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST +1
View PDF 9 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST
- Filing Date
- 2021-10-08
- Publication Date
- 2026-06-18
AI Technical Summary
Technical Problem
There is a lack of methods to determine the efficacy or sensitivity of anti-transferrin receptor antibodies, which are useful in treating diseases such as cancer.
Method used
Intracellular iron levels are used as an indicator to assess the efficacy or sensitivity of anti-transferrin receptor antibodies, with lower iron levels indicating higher drug efficacy.
Benefits of technology
This method allows for the determination of anti-transferrin receptor antibody efficacy, particularly in treating blood cancers like acute myeloid leukemia, by measuring intracellular iron levels.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007875530000004 
Figure 0007875530000005 
Figure 0007875530000006
Abstract
The present invention addresses the problem of providing a method for determining the sensitivity or medicinal effect of an anti-transferrin receptor antibody. The present invention provides a method that is for determining the sensitivity or medicinal effect of an anti-human transferrin receptor antibody having an effect of inhibiting binding between human transferrin and a human transferrin receptor, and that uses the amount of intracellular iron as an index.
Need to check novelty before this filing date? Find Prior Art